HIGHLIGHTS
- who: September et al. from the Hospital of the Chinese People`s Liberation Army, China Army Medical University, China have published the Article: Cost-effectiveness of osimertinib versus standard EGFR-TKI as fi rst-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China, in the Journal: (JOURNAL)
- what: The aim of this study was to evaluate the economics of osimertinib versus firstgeneration EGFR-TKI (gefitinib or erlotinib) as the first-line treatment of untreated EGFR mutation-positive advanced NSCLC based on the FLAURA trial results from the perspective of the Chinese . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.